Taken together, the data in the previous (19) and current studies suggest that the molecular mechanism underlying induction of synthetic lethality by simultaneous inhibition of CBP/p300 in cBAF-deficient cancers is as follows: localization of the cBAF complexes to the promotor region of the KREMEN2 gene locus leads to transcriptional repression of the KREMEN2 gene. This evidence concerns the gene EP300 and cancer.